We carried out an investigation on rabies virus-like particles (RV-VLPs) expressed in HEK293 cells using serum free medium. These RV-VLPs were formulated with two different adjuvants in order to analyse the enhancement of the triggered immune response and its stability. In experiments in mice, RV-VLPs showed an enhanced humoral immune response when injected with adjuvant, in contrast to the obtained for the RV-VLPs without adjuvant addition. Besides, higher titers of neutralizing antibodies were induced when RV-VLPs were formulated with LipoSap® in comparison with the obtained with Alhydrogel®.

At the same time, the positive effect of this adjuvant in vaccine’s potency and stability was demonstrated, showing that LipoSap® significantly increases the value obtained in NIH efficiency test for rabies vaccine, and proving that this value is maintained after 15 months storage at 4 °C.

Further, we showed that RV-VLPs induces an immune response based on neutralizing antibodies when cat, dogs and bovines were vaccinated with only one dose of RV-VLPs. These results demonstrated that this vaccine candidate could be applied for the prevention of rabies in pets as well as for the control of paralytic rabies in cattle.

我们使用无血清培养基对 HEK293 细胞中表达的狂犬病病毒样颗粒 (RV-VLP) 进行了研究。这些 RV-VLP 与两种不同的佐剂一起配制，以分析触发的免疫反应的增强及其稳定性。在小鼠实验中，与未添加佐剂的 RV-VLP 相比，注射佐剂时 RV-VLP 表现出增强的体液免疫反应。此外，与使用 Alhydrogel ®制备的 RV-VLP相比，使用 LipoSap ®配制的 RV-VLP 可诱导更高滴度的中和抗体。

同时，证明了这种佐剂对疫苗效力和稳定性的积极影响，表明 LipoSap ®显着提高了 NIH 狂犬病疫苗效率测试中获得的值，并证明该值在 4° 储存 15 个月后仍保持不变C。

此外，我们表明，当猫、狗和牛只接种一剂 RV-VLP 时，RV-VLP 会诱导基于中和抗体的免疫反应。这些结果表明，该候选疫苗可用于预防宠物狂犬病以及控制牛的麻痹性狂犬病。